Search research articles
Contact Us
Filters
Showing results (21-30 of 69) with videos related to
Page
of 7
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Ian Krop, Nofisat Ismaila, Fabrice Andre, et al.
Cancer Treatment Reviews
|
March 19, 2024
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Rebecca S Heist, Jacob Sands, Aditya Bardia, et al.
Genome Medicine
|
April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers
Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Cancer Discovery
|
March 28, 2020
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Junji Tsurutani, Hiroji Iwata, Ian Krop, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
International Journal of Cancer
|
January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
Breast Cancer Research and Treatment
|
March 7, 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis
Antonio Giordano, Noah Graham, Ayal A Aizer, et al.
The Lancet. Oncology
|
May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Tanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Nature Communications
|
May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 69) with videos related to
Sort By:
Page
of 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 11, 2017
Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update
Ian Krop, Nofisat Ismaila, Fabrice Andre, et al.
Cancer Treatment Reviews
|
March 19, 2024
Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Rebecca S Heist, Jacob Sands, Aditya Bardia, et al.
Genome Medicine
|
April 26, 2023
Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2-, PIK3CA-mutated breast cancers
Katherine E Hutchinson, Jessica W Chen, Heidi M Savage, et al.
Cancer Discovery
|
March 28, 2020
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors
Junji Tsurutani, Hiroji Iwata, Ian Krop, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
April 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
International Journal of Cancer
|
January 26, 2019
First-in-human, phase I study of PF-06647263, an anti-EFNA4 calicheamicin antibody-drug conjugate, in patients with advanced solid tumors
Ignacio Garrido-Laguna, Ian Krop, Howard A Burris, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
March 30, 2026
CLO26-104: TBCRC 050: A Phase 1b/2 Trial of Niraparib and Trastuzumab in HER2+ Metastatic Breast Cancer (MBC): Safety and Efficacy
Erica Stringer-Reasor, Yufeng Li, Jianqing Zhang, et al.
Breast Cancer Research and Treatment
|
March 7, 2026
A phase II study of atezolizumab in combination with stereotactic radiation for patients with triple-negative breast cancer and brain metastasis
Antonio Giordano, Noah Graham, Ayal A Aizer, et al.
The Lancet. Oncology
|
May 2, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): patient-reported outcomes from a randomised, open-label, multicentre, phase 3 trial
Tanja Fehm, Francesco Cottone, Kyle Dunton, et al.
Nature Communications
|
May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
Page
of 7